The serine-threonine kinase AKT, also known as protein kinase B (PKB), was identified in 1977 as the proto-oncogene of the v-Akt oncogenic murine thymoma virus.1 Subsequent research has demonstrated that genetic events activating Akt occur in most types of cancer. Activation of Akt promotes many of the processes critical to the malignant phenotype. Thus, Akt is an attractive therapeutic target for cancer.
Drug targets for cancer: Akt research reagents
Other vital drug targets for cancer likeAkt:
Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer[J]. Targeting PI3K/mTOR signaling in cancer, 2014: 47.
Davies M A. Regulation, role, and targeting of Akt in cancer[J]. Journal of Clinical Oncology, 2011, 29(35): 4715-4717.